fucose transmembrane transporter activity
Definition
Target type: molecularfunction
Enables the transfer of fucose from one side of a membrane to the other. Fucose is 6-deoxygalactose and has two enantiomers, D-fucose and L-fucose. [GOC:ai, GOC:mtg_transport, ISBN:0815340729]
Fucose transmembrane transporter activity refers to the facilitated movement of fucose molecules across cell membranes. This process is essential for various cellular functions, including:
1. **Glycosylation:** Fucose is a crucial component of many glycoconjugates, including glycoproteins and glycolipids, which play vital roles in cell-cell interactions, immune recognition, and signal transduction. Fucose transporters ensure adequate fucose supply for these processes.
2. **Glycosphingolipid synthesis:** Fucose is a key component of glycosphingolipids, a class of lipids found on the outer surface of cell membranes. These lipids contribute to cell adhesion, signaling, and immune response. Fucose transporters deliver fucose to the site of glycosphingolipid synthesis.
3. **Blood group antigen synthesis:** Fucose is involved in the biosynthesis of blood group antigens, such as the H antigen, which determines blood type. Fucose transporters facilitate the transport of fucose to the Golgi apparatus, where blood group antigens are synthesized.
4. **Mucopolysaccharide biosynthesis:** Fucose is also incorporated into mucopolysaccharides, which are complex carbohydrates found in extracellular matrix and connective tissues. Fucose transporters ensure the availability of fucose for mucopolysaccharide synthesis.
5. **Immune function:** Fucose plays a role in immune regulation and immune cell trafficking. Fucose transporters are involved in the transport of fucose to immune cells, contributing to proper immune function.
Fucose transmembrane transporter activity is a complex process regulated by various factors, including substrate availability, pH, and membrane potential. The malfunction of these transporters can lead to impaired glycosylation, altered cell signaling, and immune system dysfunction.'
"
Proteins (1)
| Protein | Definition | Taxonomy |
|---|---|---|
| Sodium/glucose cotransporter 1 | A sodium/glucose cotransporter 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P13866] | Homo sapiens (human) |
Compounds (15)
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| phloretin | dihydrochalcones | antineoplastic agent; plant metabolite | |
| phlorhizin | aryl beta-D-glucoside; dihydrochalcones; monosaccharide derivative | antioxidant; plant metabolite | |
| vexibinol | sophoraflavanone G : A tetrahydroxyflavanone having a structure of naringenin bearing an additional hydroxyl substituent at position 2' as well as a (2R)-5-methyl-2-(prop-1-en-2-yl)hex-4-en-1-yl (lavandulyl) substituent at position 8'. vexibinol: flavanol from Sophora; structure in first source; RN given refers to (S-(R*,S*))-isomer | (2S)-flavan-4-one; 4'-hydroxyflavanones; tetrahydroxyflavanone | antimalarial; antimicrobial agent; antioxidant; plant metabolite |
| 2',4',6'-Trihydroxydihydrochalcone | chalcones | ||
| 2',4',6'-trihydroxychalcone | pinocembrin chalcone : A member of the class of chalcones that is trans-chalcone substituted by hydroxy groups at positions 2', 4' and 6' respectively. pinocembrin chalcone: isolated from Helichrysum trilineatum; structure in first source | chalcones | antifungal agent; plant metabolite |
| sergliflozin etabonate | sergliflozin: a hypoglycemic agent that inhibits SGLT2 sodium-glucose transporter; structure in first source | glycoside | |
| remogliflozin etabonate | remogliflozin etabonate: orally administered hypoglycemic agent; structure in first source | glycoside | |
| dapagliflozin | aromatic ether; C-glycosyl compound; monochlorobenzenes | hypoglycemic agent; sodium-glucose transport protein subtype 2 inhibitor | |
| ipragliflozin | glycoside | ||
| empagliflozin | aromatic ether; C-glycosyl compound; monochlorobenzenes; tetrahydrofuryl ether | hypoglycemic agent; sodium-glucose transport protein subtype 2 inhibitor | |
| 1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitol | diarylmethane | ||
| nothofagin | nothofagin: a dihydrochalcone | ||
| canagliflozin | canagliflozin hydrate : A hydrate that is the hemihydrate form of canagliflozin. Used for treatment of type II diabetes via inhibition of sodium-glucose transport protein subtype 2. | C-glycosyl compound; organofluorine compound; thiophenes | hypoglycemic agent; sodium-glucose transport protein subtype 2 inhibitor |
| pf 04971729 | ertugliflozin: structure in first source | diarylmethane | |
| deberza | 2-benzofurans |